Novo Nordisk Launches Wegovy in India to Combat Rising Obesity Rates
The Danish pharmaceutical company, Novo Nordisk, has launched Wegovy (semaglutide) in India, a weight-loss medication, targeting the rapidly increasing obesity crisis in the country. This drug is prescribed for patients with a Body Mass Index (BMI) of 30 or higher, or those with a BMI of 27 or greater and pre-existing conditions such as diabetes, high blood pressure, or other comorbidities.
India is experiencing a significant rise in obesity, driven by factors like urbanization, unhealthy lifestyles, and dietary habits. Recent national health surveys indicate that approximately 20% of the urban population in India falls into the obese category. This growing concern is contributing to a rise in cardiovascular diseases, diabetes, hypertension, and other serious health issues.
What is Wegovy?
Wegovy is a medication containing the active ingredient semaglutide, administered as an injection once a week. It’s designed for long-term weight management and to reduce the risk of major cardiovascular events, such as stroke or heart attack. It’s available in five different dosages: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg.
Price and Dosage Details
Here’s a breakdown of the prices for Wegovy available in India:
- 0.25 mg – ₹17,345
- 0.5 mg – Approximately ₹18,500
- 1 mg – Over ₹20,000
- 1.7 mg – Up to ₹24,000
- 2.4 mg – ₹26,015
Dosages are determined based on individual needs, tolerance, and the advice of a healthcare professional.
How Wegovy Works
Semaglutide is a GLP-1 receptor agonist that signals to the brain that the stomach is full, reducing appetite. This leads to decreased food intake and gradual weight loss. Furthermore, the drug improves the body’s insulin sensitivity, which can help mitigate the risk of diabetes.
Who Can Take This Medication?
According to Vikrant Shrotri, Managing Director of Novo Nordisk India, Wegovy should only be taken under the guidance of a doctor. It’s suitable for individuals with a BMI of 30 or higher, or those with a BMI of 27 or greater who have pre-existing conditions like high blood pressure, type 2 diabetes, or other comorbidities.
Is This Medication Right for Everyone?
Weight-loss medications are not a magic solution. Wegovy is most effective when combined with a balanced diet, regular exercise, and lifestyle changes. It’s important to note that the medication may also cause side effects such as nausea, diarrhea, constipation, and fatigue. Therefore, it should not be taken without consulting a doctor.
Comparison with Mounjaro
Eli Lilly’s weight-loss medication, Mounjaro, was also launched in India in March of this year. Mounjaro is available in dosages of 2.5 mg and 5 mg and its price ranges from ₹14,000 to ₹17,500 per month. While both medications aim to reduce weight, their mechanisms of action and effects may differ. Experts believe that Mounjaro is more effective for patients with type 2 diabetes, while Wegovy is more targeted towards weight management.
Accessibility of These Medications
The prices of Wegovy and Mounjaro are significantly higher than the average Indian income level, making them inaccessible to many individuals. Experts suggest that the government or insurance companies should consider including these medications in health insurance plans to enable more people struggling with obesity to benefit from them.
